Short-term Outcomes of Iridoplasty for Persistent Angle Closure Despite Patent Iridotomies (ALPIECA)
Angle Closure Glaucoma, Glaucoma
About this trial
This is an interventional treatment trial for Angle Closure Glaucoma focused on measuring iridoplasty, angle, glaucoma, anterior chamber, laser treatment
Eligibility Criteria
Inclusion Criteria:
- Patients with an occludable angle in more than two quadrants in dark room dynamic gonioscopy and patent iridotomies of at least 2 weeks were included
- A supplemental diagnosis regarding the etiology of persistent angle closure by ultrabiomicroscopy and A-scan ultrasound was obtained.
Exclusion Criteria:
- Patients with synechiae of more than one quadrant
- Advanced glaucomatous damage
- Prompt cataract surgery plans and those who did not wish to participate were excluded
Sites / Locations
- "Fundación Conde de Valenciana" Ophthalmology Institute
Arms of the Study
Arm 1
Experimental
Argon Laser Peripheral Iridoplasty
ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.